Atul Ltd. Overview
Atul Ltd is one of India's oldest and most diversified integrated chemical companies, founded in 1947 by Kasturbhai Lalbhai and still promoter-led as part of the Lalbhai Group. From a 1,300-acre flagship complex in Valsad district, Gujarat, and seven other production sites, it makes about 900 products and 400 formulations under 142 brands for some 4,000 customers in 88 countries across 32 industries (AM26). Its portfolio runs from chlor-alkali and bulk intermediates through epoxy resins, textile dyes, aromatics, crop protection actives, active pharmaceutical ingredients and retail adhesives. It reports two segments, Life Science Chemicals and Performance and Other Chemicals. FY2026 consolidated revenue was ₹6,274 crore with profit after tax of ₹689 crore, and the group ended the year with ₹1,578 crore of treasury funds net of borrowings. The investment case rests on monetising a completed capex cycle, backward integration, and a net-cash balance sheet, offset by commodity exposure and modest returns on capital.
A note on identifiers. One secondary source (Equitybulls, July 2026) printed the BSE code as 531000. This conflicts with the BSE scrip code 500027 shown by Screener and by the company's own Regulation 30 filing coverage, and is treated here as an error in that source.
The company's own description. Atul describes itself as "an integrated chemical company with robust in-house infrastructure and a comprehensive product portfolio serving diverse industrial sectors worldwide" (AM26). The FY2025 integrated report characterises it as one of the largest integrated chemical companies in India, a diversified enterprise and part of the Lalbhai Group, catering to the needs of various industries (IAR25). The profile disclosed at the April 2026 analyst meet is: 8 production sites, 142 brands, a 73 MW captive power plant, 32 industries served, 32 MLD of effluent treatment capacity, about 4,000 customers, roughly 900 products and 400 formulations, and sales into 88 countries (AM26).
Independent characterisation. Atul is best understood as a chemistry conglomerate assembled over seven decades around a single very large integrated site. It is not a pure specialty chemical company. Its economics combine three distinct types of business. The first is commodity and near-commodity production, including caustic soda and chlorine, sulphuric acid, liquid epoxy resin, and sulphur black dyes, where margins track input spreads and Chinese supply. The second is a set of niche global positions in intermediates and actives, such as para-cresol and its derivatives, resorcinol, 1,3-cyclohexanedione, dapsone, sulfones, 2,4-D and indoxacarb, where Atul has scale and process know-how. The third is a small but growing branded retail layer, comprising crop protection brands sold to Indian farmers and the Lapox, Polygrip and Lacare adhesives and care brands sold through distributors.
Business model. The model is manufacturing-led and vertically integrated. Atul produces its own chlorine, caustic, sulphuric acid, phosgene, monochloroacetic acid (through the Anaven joint operation with Nouryon) and several key intermediates, and consumes a meaningful share of these captively. Inter-segment and intra-group transfers are therefore large: FY2026 segment revenue including inter-segment transfers was ₹1,805 crore for Life Science Chemicals and ₹4,609 crore for Performance and Other Chemicals, against consolidated revenue of ₹6,274 crore (AM26). The July 2026 decision to build MCPP-p and MCPA capacity is a textbook example of the model: both herbicides are derived from o-cresol and monochloroacetic acid, which the group already makes (Business Upturn, 24 July 2026).
Revenue model. Revenue is overwhelmingly from the sale of manufactured goods. There is no subscription or licensing stream of any significance. A small "Others" segment includes agribiotech (tissue-cultured date palms), food products and services; it contributed ₹25.98 crore in Q1 FY2027 (Q1FY27). The split between business-to-business and retail sales is not disclosed in a single figure, but the two explicitly retail sub-segments are small: Crop Protection – Retail recorded ₹278 crore in FY2026, and Polymers – Retail is not separately quantified in the slides retrieved (AM26).
Value chain position. Atul sits in the middle of the chemical value chain. It buys petrochemical and inorganic feedstocks (phenol, toluene, epichlorohydrin and bisphenol-A inputs, salt, sulphur, benzene derivatives), converts them through multi-step synthesis, and sells intermediates, actives, resins, dyes and formulations to formulators, compounders, textile processors, agrochemical majors, pharmaceutical companies, tyre makers, paint companies, wind-blade makers and, at the retail end, to farmers and tradespeople.
Customer types and end-markets. The company lists the following industries served: adhesives, aerospace and defence, agriculture, automobile, composites, construction, cosmetics, dyestuff, electrical and electronics, flavour and fragrance, foam and furnishing, food and beverage, footwear, foundry, furniture, glass, handicraft, home care, horticulture, health care, marine, paint and coatings, paper, personal care, pharmaceuticals, rubber, soap and detergent, sport and leisure, stone care, textile, tyre and wind energy (AM26).
Geographic model. India is the larger market and is growing faster. In FY2026, revenue in India grew 14% (12% volume, 2% price) and revenue outside India grew 7% (5% volume, 2% price) (AM26). Overseas subsidiaries in the USA, Europe, China, Brazil, the Middle East and Ireland exist, in the company's words, "to work closely with customers" (AM26).
Strategy
Stated strategy. At the April 2026 analyst meet, under the theme "Rooted | Responsible | Rising", management set out "five enduring mandates" for "securing the future" (AM26):
-
Achieve excellence in R&D, technology and manufacturing.
-
Pervade technology (AI and others) across all functions.
-
Become world-class in people productivity and remain lean on fixed cost.
-
Conserve cash, measuring performance by free cash flow.
-
Work closely with consumers and customers to identify big ideas, but start small.
Growth themes. For B2B, growth is to come through existing, downstream and upstream products, related products, new product groups and new businesses. For B2C, through existing products, related products, new product groups and new businesses. The stated routes are to "build, form joint ventures, acquire" (AM26).
Medium-term targets. Atul does not publish numeric guidance. Its long-range slide plots revenue of ₹1,044 crore (FY2008), ₹2,043 crore (FY2013), ₹3,338 crore (FY2018) and ₹5,428 crore (FY2023), each a 63–96% increase over five years, and leaves FY2028 as a question mark with the caption that the best way to predict the future is to create it. A continuation of the historical pattern would imply FY2028 revenue in the region of ₹8,800–9,000 crore; that is an inference from the chart, not management guidance.
Latent capacity. The central operating message is that growth for the next two to three years requires little new capital. Management quantified sales yet to be realised at ₹600 crore from new projects and ₹1,100 crore from existing capacity (AM26). Sub-segment disclosure of unrealised sales potential totals: Polymers – Performance Materials ₹650 crore, Colors ₹310 crore, Aromatics ₹212 crore, Anaven ₹137 crore, Atul Bioscience ₹110 crore, Bulk Chemicals and Intermediates ₹83 crore, Crop Protection – Bulk Actives ₹80 crore, Pharmaceuticals ₹65 crore and Floras ₹54 crore, which sum to ₹1,701 crore (AM26). A year earlier, management had cited more than ₹2,500 crore of unrealised potential, of which about ₹1,700 crore from recently concluded capex and ₹800 crore from unutilised capacity (Trendlyne summary of broker note, 2025). One broker cites ₹1,800–2,000 crore after Q1 FY2027 (HDFC Sky).
Initiatives announced or completed in the last 24 months
Products & Services
Product counts, customer counts, market-share descriptors and competitor counts below are from AM26 and refer to FY2026. Atul discloses market share numerically only for selected products; elsewhere it uses "significant" or "insignificant", qualified as global (G) or India (I). Pricing models are not disclosed for any product line; sales are understood to be on negotiated contract and spot terms for B2B products and list-price-less-scheme terms through distributors for retail products.
Life Science Chemicals
| Product | Description | Position disclosed |
|---|---|---|
| 2,4-D (acid, salts, esters) | Phenoxy herbicide for broadleaf weed control; Atul was the first Indian producer of 2,4-D acid | 13% global share; competitors in Australia (1), Asia (8), Europe (1), North America (1), South America (1) |
| Indoxacarb | Oxadiazine insecticide | 14% global share; six Asian competitors |
| Sulfonylurea herbicides | Low-dose herbicide family | Named as a key product group (SCR citing AR26); share not disclosed |
| MCPP-p (mecoprop-p) and MCPA | Phenoxy herbicides; new greenfield units of 1,000 TPA and 750 TPA approved July 2026, completion targeted in 67 weeks | No existing capacity; ₹167 crore investment excluding working capital and GST |
| Other herbicides, insecticides, fungicides | Balance of the 36-product range | Not itemised in sources retrieved |
| Brand | Category | Market share (FY2026) |
|---|---|---|
| Zura | Herbicide brand | 29% |
| Salix | Herbicide brand (2,4-D based) | 28% |
| Cyno | Brand in its category | 32% |
| Sindica | Brand in its category | 13% |
| Amsac | Brand in its category | 11% |
| Rymix, Rhyzo, Loxo | Named best-selling brands | Share not disclosed |
| Mylonis (launched May 2026) | Patented fungicide combining azoxystrobin, isoprothiolane and mancozeb for rice sheath blight, blast and grain discolouration | New |
| Salix Gold (launched May 2026) | 2,4-D sodium salt water-dispersible granule for post-emergence control of broadleaf weeds and sedges in rice | New |
| Tikadis (launched May 2026) | Patented seed treatment combining azoxystrobin, carbendazim and thiamethoxam for groundnut and soybean | New |
| Product | Description | Position disclosed |
|---|---|---|
| Dapsone | Anti-infective API; USFDA-approved facility since 2015 | Significant global share; competitors in India and Europe |
| 1-CEIC | Phosgene-derived intermediate | Significant India share; competition from China |
| Phosgene chemicals | Chloroformates, isocyanates and carbamates family | Insignificant global share; two producers in North America and Europe are expected to exit, which Atul flags as a share opportunity |
| APIs and intermediates (Atul Bioscience) | Therapeutic areas include antiasthmatic, antidepressant, antidiabetic, antifungal, anti-infective, anti-inflammatory, antineoplastic, antiretroviral and cardiovascular; also contract manufacturing | 11 DMFs filed in FY2026 |
Crop Protection – Bulk Actives (36 products, 224 customers; serves agriculture and public health; addressable market cited as US$77 billion for crop protection and US$1 billion for public health)
FY2026 sub-segment sales grew 16% in value and 10% in volume; two new products were launched and five developed for FY2027 launch (AM26). FY2025 sales were ₹627 crore, up 28% from ₹491 crore (FY2025 MD&A via IIFL).
Crop Protection – Retail (71 formulations under 59 brands, 2,099 customers; India agriculture market cited at ₹12,000 crore growing 7%)
Market shares are within each product's own category in India as defined by Atul. Sales were ₹195 crore (FY2023), ₹203 crore (FY2024), ₹253 crore (FY2025) and ₹278 crore (FY2026). In FY2026 the business secured registrations for three in-house developed products, launched four products including one biological, and entered eastern Maharashtra (AM26; NewsVoir release, May 2026).
Pharmaceuticals (90 products, 300 customers; addressable markets cited at ₹7,000 crore for pharmaceuticals and ₹1,000 crore for specialty chemicals)
Floras (2 products, 242 customers): tissue-cultured date palm plantlets through Atul Rajasthan Date Palms and DPD Ltd, with a significant global share against 32 competitors across Asia, Africa, Europe, North America and India. FY2026 sales rose 16% in value and 18% in volume, and in-vitro plantlets were exported (AM26).
Performance and Other Chemicals
| Product | Description | Position disclosed |
|---|---|---|
| p-Cresol | Core aromatic intermediate; Atul was first to make it in India | Significant global share; four Asian competitors |
| p-Cresol derivatives (p-Cd) | Downstream antioxidants and intermediates | Significant global share |
| p-Anisic aldehyde | Fragrance and UV-filter intermediate (tagged LSC) | Significant global share |
| p-Anisyl alcohol | Fragrance ingredient (tagged LSC) | Significant India share |
| Product | Description | Position disclosed |
|---|---|---|
| Resorcinol | Used in tyre adhesion, UV stabilisers and resins | Significant India share; three Asian competitors |
| Resorcinol-formaldehyde resins | Tyre and rubber adhesion promoters | Significant India share |
| 1,3-Cyclohexanedione | Herbicide intermediate | Significant global share |
| Caustic soda and chlorine | Chlor-alkali, largely via Atul Products Ltd | Significant in South Gujarat and Maharashtra |
| Sulphuric acid | Including via Amal Ltd | Significant in South Gujarat |
| Monochloroacetic acid | Via Anaven LLP with Nouryon | Share not disclosed |
| Product | Description | Position disclosed |
|---|---|---|
| Epoxy resins and curing agents | Liquid epoxy resin (50 KT plant), specialty epoxies and hardeners for coatings, construction, electrical, composites, adhesives and aerospace | Significant India share; competitors in India (3), Asia (8), Europe and USA (6) |
| Reactive diluents | Viscosity modifiers for epoxy systems | Significant India share |
| Sulfones | Including DDS used as a high-performance curing agent | Significant global share |
| Brand | Category | India market share (FY2026) |
|---|---|---|
| Lapox | Epoxy adhesives and construction chemicals | 7% |
| Polygrip | Rubber-based and synthetic adhesives for footwear, furniture and foam | 6% |
| Lacare | Care products | 1% |
Aromatics (37 products, 405 customers; end-uses in additives, fragrance and personal care)
FY2026 sales fell 6% in value and 7% in volume. Three new products were commercialised and hybrid power use rose from 36% to 55% (AM26).
Bulk Chemicals and Intermediates (23 products, 249 customers)
FY2026 sales rose 5% in value with volume down 1% (AM26).
Colors (525 products, 345 customers): vat dyes (significant India and global share against 13 Indian and 30 overseas competitors), sulphur black (significant in India, insignificant globally), other textile dyes including reactive and disperse (insignificant share in a field of about 210 Indian and 400 overseas competitors), and high-performance pigments (insignificant global share). Eleven new liquid sulphur colour products were launched in FY2026; sales rose 9% in value and 5% in volume. Rudolf Atul Chemicals adds textile auxiliaries and introduced 27 new products in FY2026, contributing 11% of its sales (AM26).
Polymers – Performance Materials (49 products, 202 formulations, 511 customers)
This is the group's largest business: sales of ₹1,268 crore (FY2023), ₹1,194 crore (FY2024), ₹1,446 crore (FY2025) and ₹1,710 crore (FY2026), with international sales at 45%, 40%, 40% and 38% respectively. FY2026 growth was 18% in value and 21% in volume (AM26).
Polymers – Retail (82 products, 618 customers)
FY2026 sales grew 20% in value and 19% in volume. A distributor loyalty programme and construction and PVA adhesives lines were introduced (AM26).
Financial Narrative
All figures consolidated, ₹ crore. FY2022–FY2026 income statement, balance sheet and cash flow lines are from SCR unless stated; FY2025–FY2026 company-reported figures are from AM26. Indian Accounting Standards do not require a gross profit line and Atul does not report one, so gross profit and gross margin are not publicly disclosed.
Income statement
Notes: EBITDA for FY2024–FY2026 is as reported by the company (IAR24; AM26); FY2022–FY2023 EBITDA and all EBIT figures are derived as operating profit plus other income, less depreciation. Other income for FY2025–FY2026 per the company is ₹109 crore and ₹203 crore, slightly different from SCR's classification. Diluted EPS is not separately verified; Atul has no known dilutive instruments, so diluted EPS is expected to equal basic. Dividend per share is derived from the dividend percentages on a ₹10 face value disclosed in AM26 (250%, 325%, 200%, 250%, 300%); FY2023 includes a one-time 75% special dividend, and the FY2026 dividend was proposed in April 2026 for approval at the 31 July 2026 AGM.
Margins and growth
Derived. Revenue CAGR FY2022–FY2026 (four years) is 5.4%; FY2021–FY2026 (five years, from ₹3,731 crore) is 11.0%, matching SCR's five-year compounded sales growth.
Balance sheet (as at 31 March)
Sources: SCR; treasury funds from AM26. The company's own presentation shows total assets of ₹7,001 crore (FY2025) and ₹7,900 crore (FY2026) and total equity including non-controlling interests of ₹5,662 crore and ₹6,296 crore; the differences from SCR reflect classification and the treatment of minority interest. Net debt is negative in every year, so the group is in a net cash position equal to the treasury funds line. CARE noted that on a standalone basis Atul had only cash credit limits on its books at 31 March 2025, so group borrowings sit mainly in subsidiaries (CARE, 1 October 2025).
Working capital (company basis, excluding liquid investments)
Source: AM26. Management states net working capital improved by 10 days in FY2026.
Cash flow
Sources: SCR; capex trend from AM26, which notes that expenditure differs from the amount capitalised. Cash-flow-statement capex was ₹246 crore in FY2025 and ₹172 crore in FY2026; dividends paid were ₹59 crore and ₹74 crore (AM26).
Ratios
ROE, ROA, debt to equity, interest coverage and asset turnover are derived from the tables above using average balances; ROCE and the working capital days are from SCR. Net debt to EBITDA is negative throughout (net cash). The company's own RoCE figures differ by definition: 23.6% (FY2022), 19.2% (FY2023) and 12.5% (FY2024) in IAR25, while AM26 reports 15% for FY2025 and 17% for FY2026 on average capital employed of ₹4,872 crore and ₹5,525 crore; IAR25 shows 13.7% for FY2025. The two FY2025 figures conflict and likely reflect standalone versus consolidated bases. The current ratio was 2.96x at 31 March 2025 (CARE); on the AM26 balance sheet it is 3.3x for FY2025 and 3.6x for FY2026 (derived, consolidated).
Quarterly progression
Source: SCR.
Commentary on trends and drivers.
Revenue: FY2022 was a post-pandemic price peak, FY2023 held on prices, and FY2024 saw a 13% fall as realisations dropped about 19% while volumes rose about 5% on a standalone basis (IAR24). Recovery since has been volume-led: FY2026 revenue grew 12%, of which roughly 10 points were volume and about 8 points came from recently completed projects (AM26).
Margins: Operating margin before other income fell from 25% in FY2021 to 13.5% in FY2024 and has recovered only to 16.5%. Depreciation nearly doubled from ₹177 crore to ₹322 crore as the capex cycle was capitalised, which is why EBIT margin (14.5%) remains below FY2022 (16.1%) despite higher revenue. Q1 FY2027's 21% operating margin is the first quarter back above 20% since FY2021; one broker attributed it partly to better pricing and inventory gains (HDFC Sky, August 2026), so its durability is unproven.
Other income: Other income doubled to about ₹203–206 crore in FY2026 and accounted for roughly 23% of PBT. It included an income tax refund of ₹47 crore from old assessments, and a subsidiary received ₹15 crore of interest assistance (AM26). Underlying earnings growth is therefore lower than the 38% reported PAT growth.
Cash flow: Operating cash flow of ₹1,023 crore in FY2026 was the highest in the company's history and capex of ₹175 crore the lowest in eleven years, producing free cash flow of about ₹851 crore. Almost all of it (₹768 crore) was placed in treasury funds, and dividends took ₹74 crore.
Returns: ROE of 11.7% is well below the 10-year average of 13% (SCR) and roughly half the FY2020–FY2021 level. A cash and investment pile approaching one-third of total assets weighs on headline returns.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segment Overview
| Segment | Sub-segments (businesses) | Principal product groups |
|---|---|---|
Life Science Chemicals | Crop Protection – Bulk Actives; Crop Protection – Retail; Pharmaceuticals; Aromatics (part: p-anisic aldehyde and p-anisyl alcohol chains are tagged LSC); Floras (shown under LSC in AM26) | Herbicides, insecticides, fungicides, APIs and API intermediates, phosgene derivatives, tissue-cultured date palms |
Performance and Other Chemicals | Aromatics (p-cresol chain); Bulk Chemicals and Intermediates; Colors; Polymers – Performance Materials; Polymers – Retail | Para-cresol derivatives, resorcinol, caustic soda, chlorine, sulphuric acid, textile dyes, pigments, epoxy resins and curing agents, sulfones, adhesives |
Others | Agribiotech, food products, services | Small; ₹25.98 crore revenue in Q1 FY2027 (Q1FY27) |
Revenue by Segment
| Segment | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Life Science Chemicals revenue (INR Cr) | 1,465 | 1,959 | 1,427 | 1,692 | 1,805 |
Performance and Other Chemicals revenue (INR Cr) | 3,759 | 3,706 | 3,453 | 4,058 | 4,609 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansSegment Margins & Growth (%)
| Segment | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
Life Science Chemicals YoY growth (%) | 33.7 | -27.2 | 18.6 | 6.7 |
Performance and Other Chemicals YoY growth (%) | -1.4 | -6.8 | 17.5 | 13.6 |
Revenue by Segment (%)
| Segment | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Life Science Chemicals share (%) | 28.0 | 34.6 | 29.2 | 29.4 | 28.1 |
Performance and Other Chemicals share (%) | 72.0 | 65.4 | 70.8 | 70.6 | 71.9 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansRevenue by Segment and Segment Margins & Growth (%)
| Metric | FY2025 | FY2026 |
|---|---|---|
Life Science Chemicals EBIT (INR Cr) | 347 | 417 |
Life Science Chemicals EBIT margin (%) | 20 | 23 |
Life Science Chemicals net capital employed (INR Cr) | 1,039 | 1,074 |
Life Science Chemicals RoCE (%) | 33 | 39 |
Performance and Other Chemicals EBIT (INR Cr) | 345 | 417 |
Performance and Other Chemicals EBIT margin (%) | 8 | 9 |
Performance and Other Chemicals net capital employed (INR Cr) | 2,914 | 2,936 |
Performance and Other Chemicals RoCE (%) | 12 | 14 |
Group Entities
| Entity | Atul holding | Activity | FY2026 note |
|---|---|---|---|
Atul Bioscience Ltd | 100% | APIs and intermediates; plants at Atul and Ambernath | Sales value up 9%; 11 DMFs filed in FY2026 (7 in FY2025); both units USFDA inspected |
Atul Products Ltd | 100% | Caustic soda and chlorine complex | Sales ₹504 crore (FY2025 ₹352 crore; FY2024 ₹65 crore, a partial year) |
Amal Ltd (consolidated) | 49.86% | Sulphuric acid and derivatives | Sales ₹240 crore (FY2025 ₹135 crore; FY2024 ₹86 crore; FY2023 ₹61 crore) |
Rudolf Atul Chemicals Ltd | 50% JV with Rudolf GmbH | Textile chemicals | Sales ₹161 crore (FY2025 ₹165 crore; FY2024 ₹138 crore; FY2023 ₹110 crore) |
Anaven LLP | 50:50 joint operation with Nouryon | Monochloroacetic acid | Sales value down 4%, volume down 2% |
DPD Ltd, UK | 98% | Date palm tissue culture | Phase-2 expansion inaugurated June 2025 |
Atul Rajasthan Date Palms Ltd | — | Tissue-cultured date palms | ERP implemented; ramp-up under way |
Income Statement and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue from operations (INR Cr) | 5,081 | 5,428 | 4,726 | 5,583 | 6,274 |
Operating profit before other income (INR Cr) | 913 | 807 | 639 | 918 | 1,034 |
Other income (INR Cr) | 82 | 86 | 65 | 115 | 206 |
EBITDA including other income (INR Cr) | 995 | 893 | 705 | 1,022 | 1,234 |
Depreciation (INR Cr) | 177 | 198 | 243 | 317 | 322 |
Operating income, EBIT (INR Cr) | 818 | 695 | 462 | 705 | 912 |
Interest (INR Cr) | 9 | 8 | 11 | 24 | 17 |
Profit before tax (INR Cr) | 810 | 688 | 451 | 692 | 901 |
Net profit after tax (INR Cr) | 605 | 507 | 324 | 499 | 689 |
Basic EPS (INR) | 204.23 | 174.19 | 109.71 | 164.37 | 230.25 |
Dividend per share (INR) | 25 | 32.5 | 20 | 25 | 30 |
Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue growth YoY (%) | 36.2 | 6.8 | -12.9 | 18.1 | 12.4 |
Operating margin before other income (%) | 18.0 | 14.9 | 13.5 | 16.4 | 16.5 |
EBITDA margin including other income (%) | 19.6 | 16.5 | 14.9 | 18.3 | 19.7 |
EBIT margin (%) | 16.1 | 12.8 | 9.8 | 12.6 | 14.5 |
Net margin (%) | 11.9 | 9.3 | 6.9 | 8.9 | 11.0 |
Balance Sheet
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Total assets (INR Cr) | 5,690 | 5,752 | 6,455 | 6,980 | 7,870 |
Shareholders' equity, capital plus reserves (INR Cr) | 4,429 | 4,672 | 5,114 | 5,598 | 6,221 |
Total borrowings (INR Cr) | 144 | 52 | 237 | 202 | 183 |
Fixed assets, net (INR Cr) | 1,634 | 1,770 | 2,792 | 2,847 | 2,676 |
Capital work in progress (INR Cr) | 420 | 1,033 | 281 | 124 | 110 |
Investments (INR Cr) | 1,339 | 881 | 1,392 | 1,766 | 2,592 |
Treasury funds net of borrowings (INR Cr) | 594 | 307 | 361 | 691 | 1,578 |
Liquidity & Coverage Ratios
| Metric | FY2025 | FY2026 |
|---|---|---|
Inventories (INR Cr) | 765 | 859 |
Trade receivables (INR Cr) | 1,126 | 1,271 |
Other current assets (INR Cr) | 237 | 278 |
Current liabilities (INR Cr) | 806 | 1,068 |
Net working capital (INR Cr) | 1,322 | 1,340 |
Cash Flow
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Cash from operating activities (INR Cr) | 231 | 707 | 667 | 603 | 1,023 |
Cash from investing activities (INR Cr) | -163 | -469 | -683 | -494 | -891 |
Cash from financing activities (INR Cr) | -57 | -257 | 38 | -118 | -98 |
Capital expenditure, company trend basis (INR Cr) | 591 | 874 | 504 | 270 | 175 |
Free cash flow, SCR basis (INR Cr) | -359 | -167 | 164 | 334 | 851 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Return on equity (%) | 14.7 | 11.1 | 6.6 | 9.3 | 11.7 |
Return on assets (%) | 11.4 | 8.9 | 5.3 | 7.4 | 9.3 |
Return on capital employed, SCR basis (%) | 19 | 15 | 9 | 13 | 15 |
Debt to equity (x) | 0.03 | 0.01 | 0.05 | 0.04 | 0.03 |
Interest coverage, EBIT to interest (x) | 91 | 87 | 42 | 29 | 54 |
Asset turnover (x) | 0.96 | 0.95 | 0.77 | 0.83 | 0.84 |
Debtor days | 71 | 57 | 72 | 74 | 74 |
Inventory days | 122 | 101 | 90 | 97 | 90 |
Payable days | 90 | 69 | 84 | 82 | 94 |
Cash conversion cycle (days) | 103 | 89 | 77 | 89 | 70 |
Income Statement and Margin Analysis (%)
| Metric | Q1 FY2026 | Q2 FY2026 | Q3 FY2026 | Q4 FY2026 | Q1 FY2027 |
|---|---|---|---|---|---|
Revenue (INR Cr) | 1,478 | 1,552 | 1,574 | 1,670 | 1,848 |
Operating profit (INR Cr) | 236 | 267 | 247 | 281 | 394 |
Operating margin (%) | 16 | 17 | 16 | 17 | 21 |
Profit before tax (INR Cr) | 177 | 231 | 203 | 289 | 347 |
Net profit (INR Cr) | 132 | 182 | 164 | 211 | 254 |
EPS (INR) | 43.40 | 60.88 | 54.60 | 71.38 | 83.32 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansRevenue by Region
| Region | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
India (INR Cr) | 1,964 | 2,526 | 2,868 | 2,712 | 3,328 |
Outside India (INR Cr) | 1,767 | 2,555 | 2,560 | 2,014 | 2,255 |
Region Margins & Growth (%) and Revenue by Region (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
India growth YoY (%) | 28.6 | 13.5 | -5.4 | 22.7 |
Outside India growth YoY (%) | 44.6 | 0.2 | -21.3 | 12.0 |
India share of revenue (%) | 49.7 | 52.8 | 57.4 | 59.6 |
Outside India share of revenue (%) | 50.3 | 47.2 | 42.6 | 40.4 |
Revenue by Region (FY2023–FY2024)
| Metric | FY2023 | FY2024 |
|---|---|---|
Life Science Chemicals domestic (INR Cr) | 631.82 | 701.82 |
Life Science Chemicals export (INR Cr) | 844.85 | 555.47 |
Capital Markets
| Item | Value | Source |
|---|---|---|
Share price | ₹5,861 | SCR |
52-week high / low | ₹7,198 / ₹5,560 | SCR |
Market capitalisation | ₹17,256 crore (about US$1.97 billion at end-August 2026 per PitchBook) | SCR |
Trailing P/E | 21.7x | SCR |
Price to book | 2.77x (book value ₹2,113 per share) | SCR |
Dividend yield | 0.51% | SCR |
Enterprise value | About ₹15,700 crore (market capitalisation less ₹1,578 crore of net treasury funds at March 2026; derived) | Derived |
EV / trailing sales | About 2.4x on ₹6,643 crore | Derived |
EV / trailing operating profit | About 13.2x on ₹1,189 crore, before other income | Derived |
Forward P/E | 20.76x | StockAnalysis |
Share Price & Returns
| Period | Return |
|---|---|
1 year | About minus 3% to minus 5% (ScanX minus 3.27%; SCR minus 5%) |
3 years | Minus 6% per year compounded (SCR) |
5 years | Minus 10% per year compounded (SCR); minus 38.06% cumulative (ScanX) |
10 years | Plus 9% per year compounded (SCR) |
Source Details
| Source | Date | View |
|---|---|---|
HDFC Sky (HDFC Securities retail research) | August 2026 | Buy in the ₹6,765–6,840 band; targets ₹7,341 and ₹7,784 |
Unnamed broker via ScanX | 9 January 2026 | Buy; target ₹8,500 |
Motilal Oswal via Trendlyne | FY2026 notes | — |
Trendlyne consensus | — | Average target ₹7,725 from four brokers |
Elara Capital via ScanX | 4 May 2026 | Accumulate; target price as printed not reliable |
Income Statement and Margin Analysis (%) (Annual)
| Metric | FY2027E | FY2028E |
|---|---|---|
Revenue (INR Cr) | 6,796 | 7,496 |
EBITDA (INR Cr) | 1,194 | 1,336 |
EBITDA margin (%) | 17.6 | 17.8 |
Net profit (INR Cr) | 757 | 883 |
EPS (INR) | 257.1 | 299.6 |
Per-Share Data and Returns & Leverage Ratios (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Dividend per share (INR) | 25 | 32.5 | 20 | 25 | 30 |
Payout ratio (%) | 12 | 19 | 18 | 15 | 13 |
Credit Ratings
| Agency | Rating | Outlook | Date |
|---|---|---|---|
CARE Ratings (long-term bank facilities) | CARE AA+ | Stable | Reaffirmed 1 October 2025 |
CARE Ratings (short-term bank facilities) | CARE A1+ | — | Reaffirmed 1 October 2025 |
Moody's, S&P, Fitch | Not rated | — | — |
Analyst Conclusions
Management guidance. Atul gives no numeric guidance. The qualitative message from April 2026 is to grow from capacity already built (₹1,700 crore of unrealised sales), keep capex low, measure performance by free cash flow, and embed digital tools. The only new capital commitment since is the ₹167 crore phenoxy herbicide project.
Consensus expectations. The one detailed estimate set retrieved projects revenue of ₹6,796 crore and EPS of ₹257 for FY2027 and ₹7,496 crore and ₹300 for FY2028 (HDFC Sky). After a first quarter that delivered ₹83 of EPS, upgrades are likely if margins hold.
Bull case
-
Operating leverage is arriving. Q1 FY2027 operating margin was 21% against 16–17% through FY2026, and the POC segment result rose 140% year on year. If POC sustains even a mid-teens EBIT margin on a ₹5,000 crore revenue base, group EBIT would rise by several hundred crore without new capital.
-
Growth is pre-funded. ₹1,700 crore of unrealised sales represents 27% volume headroom; capex was ₹175 crore in FY2026 against operating cash flow of ₹1,023 crore.
-
Balance sheet optionality. ₹1,578 crore of net treasury funds, about 9% of market capitalisation, can fund acquisitions in crop protection retail, further downstream integration, or a larger capital return.
Bear case
-
Earnings quality. FY2026 PAT growth of 38% was helped by a doubling of other income and a ₹47 crore tax refund; Q1 FY2027 benefited from pricing and inventory gains. Stripping these out, underlying growth is closer to revenue growth.
-
Structural returns. POC absorbs 73% of segment capital at a 14% RoCE, and the businesses where Atul added capacity (liquid epoxy, caustic soda) are those most exposed to Chinese supply. Group ROE has not exceeded 12% since FY2022.
-
Capital discipline. Cash is accumulating in treasury funds that earn less than the cost of equity, the payout ratio is only 13%, and the stated interest in acquisitions introduces execution risk for a company with little M&A history.
Catalysts and monitorables for the next 12 months
Analyst verdict. Atul enters the second half of FY2027 in its strongest financial position in seventy-nine years. Revenue is at a record, operating cash flow has crossed ₹1,000 crore, the heavy capex cycle is finished, and the balance sheet holds more than ₹1,500 crore of surplus funds. The latest quarter showed, for the first time since the 2021 peak, what the enlarged asset base can earn when prices cooperate.
Yet the evidence does not support treating Atul as a high-quality specialty compounder. Half its operating profit comes from a Life Science segment that is excellent but growing in single digits. The other half comes from a Performance segment that consumed most of the new capital and still earns returns close to the cost of capital. R&D at under 1% of revenue will not change that mix quickly, and the company's own slides show how wide the scale gap with China has become. The market's verdict, a share price lower than five years ago, is harsh but not irrational.
The balance of probabilities for the next year is nevertheless favourable. Volume headroom is real and quantified, depreciation has plateaued, interest cost is negligible, and each incremental rupee of contribution falls largely to profit. If operating margin settles at 18–19% rather than reverting to 16%, earnings per share near ₹300 are achievable a year ahead of published estimates, which would put the stock below 20 times earnings with a tenth of its value in cash.
The decisive variable is management's use of that cash. A disciplined acquisition that gives the retail brands scale, or a materially higher payout, would address the returns problem directly. Continued accumulation would not. Atul is a sound, conservatively run franchise with cyclical upside; whether it becomes more than that depends on capital allocation decisions that have yet to be made.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure | Background | Age / year of birth |
|---|---|---|---|---|
Sunil Siddharth Lalbhai | Chairman and Managing Director; promoter | MD since June 1984; Chairman since August 2007 | MS in Chemistry (University of Massachusetts) and MS in Economic Policy and Planning (Northeastern University); also Chairman of Amal Ltd; has held directorships at Britannia Industries, Navin Fluorine International, Bombay Dyeing and Pfizer Ltd at various times | Born 15 March 1960 |
Samveg Arvindbhai Lalbhai | Managing Director; promoter | Director since January 2000; MD since December 2001; reappointed for five years from 15 December 2026 | Promoter family; directorships have included Bengal Tea and Fabrics and The Anup Engineering | Born 1961 (YF) |
Gopi Kannan Thirukonda | Chief Financial Officer and Whole-time Director | CFO since July 2013; Director since October 2014 | — | Born 1959 (YF) |
Vivek Gadre | Whole-time Director | Board member since January 2025 | — | Born 1962 (YF) |
Dr Anuj Mittal | President – Research | Since 23 February 2026 | About 30 years in R&D, process innovation and commercialisation; doctorate in organic chemistry | — |
Lalit Patni | Company Secretary and Chief Compliance Officer | Compliance officer since October 2014 (MS) | — | — |
“—” = not publicly disclosed.
Directors' Remuneration
| Name | Total pay (INR Mn) |
|---|---|
Sunil Lalbhai | 134.5 |
Samveg Lalbhai | 33.92 |
Gopi Kannan Thirukonda | 25.81 |
Vivek Gadre | 24.54 |
Board of Directors
| Name | Role | On Board since | Notes |
|---|---|---|---|
Pradeep Banerjee | Independent Director | May 2022 | Member, Risk Management Committee |
Rangaswamy Iyer | Independent Director | 1 May 2023 (five-year term) | Approved at AGM of 28 July 2023 |
Sujal Shah | Independent Director | October 2023 | — |
Sharadchandra Abhyankar | Independent Director | October 2023 | Chairperson, Stakeholders Relationship Committee |
Praveen Kadle | Independent Director | May 2024 | — |
Padmaja Chunduru | Independent Director | January 2025 | — |
Vinayak Deshpande | Independent Director | August 2026 | IIT Kharagpur chemical engineer with about four decades in automation, infrastructure and EPC; DIN 00036827; five-year term approved by postal ballot, result 7 September 2026 |
Shareholding Trend
| Holder category | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|
Promoters (%) | 45.18 | 45.21 | 45.22 | 45.22 | 45.33 |
Foreign institutional investors (%) | 8.77 | 8.31 | 7.45 | 7.50 | 7.44 |
Domestic institutional investors (%) | 24.97 | 24.95 | 25.41 | 25.89 | 25.93 |
Public and others (%) | 21.05 | 21.51 | 21.92 | 21.37 | 21.30 |
Number of shareholders | 55,505 | 56,951 | 57,263 | 56,855 | 56,570 |
Competitive Landscape
Competitors by Segment
| Sub-segment | Principal competitors (named) | Atul's relative position |
|---|---|---|
Crop Protection – Bulk Actives | UPL, PI Industries, Meghmani Organics, Bharat Rasayan, Nufarm (2,4-D), Chinese phenoxy producers | 13% global share in 2,4-D and 14% in indoxacarb; mid-sized overall |
Crop Protection – Retail | UPL, Rallis India, Dhanuka Agritech, PI Industries, Bayer CropScience, Sumitomo Chemical India | Small (₹278 crore) but with category-leading brands |
Pharmaceuticals | Aarti Pharmalabs, Divi's Laboratories, Hikal, Paushak (phosgene), Chinese intermediates makers | Niche: global significance in dapsone only |
Aromatics | Chinese p-cresol producers, Lanxess, Vinati Organics (adjacent chemistries) | Significant global share in p-cresol chain |
Bulk Chemicals and Intermediates | Gujarat Alkalies and Chemicals, DCM Shriram, Grasim Industries, Meghmani Finechem (Epigral), Sumitomo Chemical (resorcinol) | Regional in chlor-alkali; nationally significant in resorcinol |
Colors | Bodal Chemicals, Kiri Industries, Jay Chemical, Archroma, DyStar, Sudarshan Chemical (pigments) | Leader in vat dyes; minor in reactive dyes and pigments |
Polymers – Performance Materials | Grasim (epoxy), Hindusthan Speciality Chemicals, Westlake Epoxy, Olin, Huntsman, Kukdo Chemical, Nan Ya Plastics | Among the top domestic epoxy producers |
Polymers – Retail | Pidilite Industries, Astral (Resinova), Jubilant Agri and Consumer Products | Challenger: Lapox 7%, Polygrip 6% |
Peer Comparison FY2026
| Metric | Atul | Aarti Industries | Deepak Nitrite | SRF |
|---|---|---|---|---|
Revenue (INR Cr) | 5,583 | 7,271 | 8,282 | 14,693 |
Revenue growth YoY (%) | 18 | 14 | 8 | 12 |
EBITDA margin (%) | 18 | 14 | 13 | 19 |
Net profit (INR Cr) | 499 | 331 | 697 | 1,251 |
R&D intensity (%) | 0.7 | — | — | — |



